Medicine and Dentistry
Gallium 68
100%
Biological Marker
92%
Prostate Cancer
82%
Non Muscle Invasive Bladder Cancer
78%
Bladder Cancer
75%
Positron Emission Tomography
73%
Prostate Specific Membrane Antigen
69%
Lymph Node Metastasis
51%
Diagnostic Performance
50%
Prostatectomy
48%
Recurrent Disease
47%
Neutrophil
46%
Meta-Analysis
46%
Systematic Review
46%
Polyethylene Terephthalate
46%
Lymphocyte
46%
Transitional Cell Carcinoma
37%
Decision Making
35%
Metastatic Carcinoma
33%
Biochemical Recurrence
31%
Neoplasm
30%
Lymph Node
29%
Clinical Decision Making
28%
Bladder
28%
Diffusion MRI
26%
Cystectomy
26%
Recurrence Free Survival
24%
Systemic Therapy
23%
Biodistribution
23%
Clinical Significance
23%
Patient Selection
23%
Androgen Deprivation Therapy
23%
Circulating Tumor DNA
23%
Germinoma
23%
Seasonal Variation
23%
Nephroureterectomy
23%
Muscle Invasive Bladder Cancer
23%
Cancer Registry
23%
Morphology
23%
Nodal Metastasis
23%
Body Mass Index
23%
Cytoreductive Surgery
23%
Computer Assisted Tomography
23%
Cancer
23%
Cross Sectional Study
23%
Kidney Injury
23%
Neoadjuvant Chemotherapy
23%
Cancer Prognosis
23%
Enfortumab Vedotin
23%
Conjugate
21%
Pharmacology, Toxicology and Pharmaceutical Science
Polyethylene Terephthalate
92%
Gallium 68
79%
Prostate Cancer
76%
Biological Marker
49%
Biochemical Recurrence
46%
Non Muscle Invasive Bladder Cancer
46%
Prostate Specific Membrane Antigen
46%
Lymph Node Metastasis
38%
Neoplasm
30%
Transitional Cell Carcinoma
26%
Recurrence Free Survival
24%
Biodistribution
23%
Cancer Prognosis
23%
Tracer
23%
Cross-Sectional Study
23%
Circulating Tumor DNA
23%
Lutetium 177
23%
Radioligand
23%
Enfortumab Vedotin
23%
Prostate Specific Antigen
15%
Dietary Supplement
11%
Recurrence Risk
9%
Disease
8%
Micrometastasis
7%
Recurrent Disease
7%
Malignant Neoplasm
6%
Cross-Validation
5%
Survival Rate
5%